Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR2 | Q92736 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 6/20 | 0.57 |
| ▸ | CD4 | P01730 | 3/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | PKLR | P30613 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1017072 | 0.92 | RYR2 (0.58) | RYR2PKMCD4AKR1C3LMNA | |
| SCHEMBL22451560 | 0.85 | RYR2 (0.61) | RYR2PKMCD4AKR1C3LMNA | |
| SCHEMBL1016818 | 0.84 | PKM (0.62) | RYR2PKMCD4AKR1C3LMNA | |
| SCHEMBL10232038 | 0.80 | CD4 (0.51) | PKMCD4AKR1C3POLBKMT2A | |
| SCHEMBL16572402 | 0.80 | MEN1 (0.55) | PKMCD4AKR1C3LMNAPOLB | |
| SCHEMBL31287301 | 0.80 | MEN1 (0.55) | PKMCD4AKR1C3LMNAPOLB | |
| SCHEMBL14640610 | 0.79 | RYR2 (0.65) | RYR2PKMCD4AKR1C3LMNA | |
| SCHEMBL19216401 | 0.78 | TSHR (0.51) | RYR2PKMCD4LMNATSHR | |
| SCHEMBL3394766 | 0.76 | ESR2 (0.55) | PKMCD4AKR1C3POLBALDH1A1 | |
| SCHEMBL16793968 | 0.76 | CD4 (0.47) | PKMCD4AKR1C3POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1409468-B9 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-1409468-B1 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-11-12 | — | — | EP | disclosed |
| US-6995269-B2 | Guanidinobenzamides | CHIRON CORPORATION (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050124652-A1 | Guanidino compounds | BOYCE RUSTUM (US) | 2005-06-09 | — | — | US | disclosed |
| EP-1478626-A2 | GUANIDINO COMPOUNDS | CHIRON CORPORATION (US) | 2004-11-24 | — | — | EP | disclosed |
| EP-1409468-A2 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | CHIRON CORPORATION (US) | 2004-04-21 | — | — | EP | disclosed |
| US-6638927-B2 | Melanocortin-4 receptor (MC4-R) agonists; treating obesity or diabetes; 4-((N-cyclohexyl-3,5-dimethyl-piperazine-1-carboximidoyl)-amino)-N-(2-(2,4 -dichlorophenyl) -ethyl)-benzamide for example | CHIRON CORPORATION | 2003-10-28 | — | — | US | disclosed |
| US-20030199499-A1 | Novel guanidinobenzamides | CHIRON CORPORATION | 2003-10-23 | — | — | US | disclosed |
| US-20030195187-A1 | Guanidino compounds | CHIRON CORPORATION | 2003-10-16 | — | — | US | disclosed |
| WO-2003066597-A2 | GUANIDINO COMPOUNDS | CHIRON CORPORATION (US) | 2003-08-14 | — | — | WO | disclosed |
| US-20020137939-A1 | Melanocortin-4 receptor (MC4-R) agonists; treating obesity or diabetes; 4-((N-cyclohexyl-3,5-dimethyl-piperazine-1-carboximidoyl)-amino)-N-(2-(2,4 -dichlorophenyl)-ethyl)-benzamide for example | CHIRON CORPORATION | 2002-09-26 | — | — | US | disclosed |
| WO-2002018327-A2 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | CHIRON CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195187-A1 | Guanidino compounds | MC4R, MC2R, GPR4 | RYR2 1421/4885PKM 2351/4885CD4 881/4885 |
| US-20030199499-A1 | Novel guanidinobenzamides | GUCY1B2, GPR119, GUCY1B1 | RYR2 1446/4885PKM 1805/4885CD4 2003/4885 |
| US-20050124652-A1 | Guanidino compounds | MC4R, MC2R, GPR4 | RYR2 1421/4885PKM 2351/4885CD4 881/4885 |
| US-20020137939-A1 | Melanocortin-4 receptor (MC4-R) agonists; treating obesity or diabetes; 4-((N-cyclohexyl-3,5-dimethyl-piperazine-1-carboximidoyl)-amino)-N-(2-(2,4 -dichlorophenyl)-ethyl)-benzamide for example | MC4R, MC5R, MC3R | RYR2 1892/4885PKM 1963/4885CD4 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.